Sisram (SRAMF), AbbVie (ABBV): Toxin Pricing Shifts to Duration

Between July 31 and August 20, 2026, AbbVie (ABBV), Evolus (EOLS) and Sisram Medical (SRAMF) each said on their own earnings calls that injectable aesthetics is now priced by how long an effect lasts rather than by who cleared an approval first. Products that cannot show a clinical difference are being pushed into discounting, while products that can are holding their price.

---

Approval scarcity ends and duration becomes the selling point

Two injectables carry this market. Botulinum toxin is injected into facial muscle to soften expression lines. Hyaluronic acid is injected under the skin to fill in lost volume. In China both need approval from the National Medical Products Administration before they can be sold, and for years the approved list was short enough that an early approval by itself set a product's price tier.

On its August 20 call, Sisram said China now has eight approved botulinum toxins with another four to six queued behind them, and that the fiercest competition sits in the medium-to-premium band — exactly where imported products had been priced [1]. Once approval stops being scarce, a seller has two options: discount into that band, or change what the customer compares. In toxins the new basis of comparison is duration, so the unit shifts from the price of one vial to how many injections a year a patient needs. A product lasting three to four months means three to four injections a year; one lasting six to nine months means one or two, and annual spending ends up close to the same [1]. Hyaluronic acid is splitting along a similar line, with volumizing fillers losing ground while the products that instead stimulate the skin's own collagen and elastin are sold as a separate category [1][3].

---

An RMB6,800 vial and a 6.6% decline at Juvederm

Sisram disclosed for the first time what the long-acting toxin DAXXIFY it licenses sells for in China: RMB6,800 per vial at the end market. The company said it does not intend to trade price for volume, and that it wants to leave more margin with the clinics [1]. AbbVie's numbers supply the other half. Second-quarter aesthetics sales were nearly $1.3 billion globally, down 0.9% operationally. Within that, Botox Cosmetic revenue was $728 million, up 3.4% operationally, while Juvederm was $245 million, down 6.6% operationally, which the company attributed to continued headwinds in key dermal filler markets [2]. On the same call, AbbVie said a fast-acting, short-duration toxin had been approved in Europe and Canada, positioned so that patients can preview the effect without worrying about long-lasting results [2]. Evolus reported $75.2 million of toxin revenue for the quarter and led its product positioning with an independent study showing the fastest onset, highest peak effect and longest duration among the toxins tested [3].

Weak demand does not explain any of this. Evolus said the US toxin market improved sequentially in the second quarter, with injection procedures returning to growth [3], and AbbVie's toxin line grew in the same quarter while only the volumizing filler declined [2]. What changed is how similar products are sorted into price tiers.

---

The clinic decides shelf space, and supply margin is what buys it

Once the vial itself is no longer scarce, the clinic decides which product gets stocked. Sisram supplies clinics directly with no distributor layer in between and says explicitly that it wants to leave more margin with the clinic [1]. That bypasses the distribution channel through which undifferentiated product still moves, and it shifts the contest from the price the patient sees to the margin the supplier gives up. Following that rule, the pressure should land on average selling prices and gross margins at mid-tier toxins and volumizing fillers.

The judgment has limits. Price compression in the medium-to-premium band is still management's forward-looking description and has not printed in any company's disclosed accounts. Injectables are only 12.9% of Sisram's revenue [1], so the company stating the rule is a new entrant in this category rather than its leader. The volume half is also unanswered: a longer-acting product keeps annual patient spending flat but reduces the number of vials used, while AbbVie is deliberately selling a short-duration product that increases injection frequency [1][2]. The metrics worth tracking from here are vials purchased per clinic per quarter and the repeat-purchase interval.

---

Companies exposed to this change

• So-Young International (SY): Now operates mainly as an owned aesthetic-clinic chain rather than an online platform, which puts it on the buying side of these injectables. Mid-to-premium toxin purchase prices feed straight into its costs, and the margin suppliers give up lands with it. The company has not disclosed anything about this repricing itself.
• Bio Plus (099430.KQ): A Korean hyaluronic acid dermal filler maker exporting mainly to China and Southeast Asia, sitting in the volumizing box AbbVie identified as under pressure, with no disclosed collagen-stimulating line to carry the margin instead.

---

Sources

[1] Drillr · Sisram Medical (SRAMF) · 2026-08-20 · earnings call

But entry of some low to medium market will impact your average selling price and your margins to some extent. So the competition on the price will be more fierce. But premium products have this uniqueness, including efficacy, branding, the duration, and it can maintain a relatively stable price.

[2] Drillr · AbbVie (ABBV) · 2026-07-31 · earnings call

[3] Drillr · Evolus (EOLS) · 2026-08-05 · earnings call

---

This is only meant to help you spot industry changes and companies that may be overlooked - it is not a stock recommendation.